The Experts below are selected from a list of 20574 Experts worldwide ranked by ideXlab platform
J J Ragland - One of the best experts on this subject based on the ideXlab platform.
-
single dose cefotetan or Cefoxitin versus multiple dose Cefoxitin as prophylaxis in patients undergoing appendectomy for acute nonperforated appendicitis
Journal of The American College of Surgeons, 1995Co-Authors: Michael A. Liberman, Sheelagh Frame, Kevin L Greason, J J RaglandAbstract:OBJECTIVE: A prospective, double-blind study was performed to examine the effects of prophylactic cefotetan and Cefoxitin in postoperative wound infection for patients with nonperforated acute appendicitis. METHODS: One hundred thirty-six of 179 patients with a clinical diagnosis of appendicitis were evaluated and divided into three groups: group 1 received 2 g cefotetan preoperatively, group 2 received 2 g Cefoxitin preoperatively, and group 3 received 2 g Cefoxitin preoperatively followed by three postoperative doses. RESULTS: The overall wound infection rate was 4.6 percent. Group 2 (single-dose Cefoxitin) had a significantly higher wound infection rate (11.1 percent) than group 1 (single-dose cefotetan) (zero percent) or group 3 (multiple-dose Cefoxitin) (1.9 percent). CONCLUSIONS: Single-dose cefotetan and multiple-dose Cefoxitin are equally effective. However, because of the greater convenience and markedly decreased cost, single-dose cefotetan is the prophylaxis of choice in appendectomy for nonperforated appendicitis.
Michael A. Liberman - One of the best experts on this subject based on the ideXlab platform.
-
single dose cefotetan or Cefoxitin versus multiple dose Cefoxitin as prophylaxis in patients undergoing appendectomy for acute nonperforated appendicitis
Journal of The American College of Surgeons, 1995Co-Authors: Michael A. Liberman, Sheelagh Frame, Kevin L Greason, J J RaglandAbstract:OBJECTIVE: A prospective, double-blind study was performed to examine the effects of prophylactic cefotetan and Cefoxitin in postoperative wound infection for patients with nonperforated acute appendicitis. METHODS: One hundred thirty-six of 179 patients with a clinical diagnosis of appendicitis were evaluated and divided into three groups: group 1 received 2 g cefotetan preoperatively, group 2 received 2 g Cefoxitin preoperatively, and group 3 received 2 g Cefoxitin preoperatively followed by three postoperative doses. RESULTS: The overall wound infection rate was 4.6 percent. Group 2 (single-dose Cefoxitin) had a significantly higher wound infection rate (11.1 percent) than group 1 (single-dose cefotetan) (zero percent) or group 3 (multiple-dose Cefoxitin) (1.9 percent). CONCLUSIONS: Single-dose cefotetan and multiple-dose Cefoxitin are equally effective. However, because of the greater convenience and markedly decreased cost, single-dose cefotetan is the prophylaxis of choice in appendectomy for nonperforated appendicitis.
E Bille - One of the best experts on this subject based on the ideXlab platform.
-
pharmacological study of Cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended spectrum β lactamase producing escherichia coli
Antimicrobial Agents and Chemotherapy, 2014Co-Authors: Olivier Joinlambert, Helene Guetrevillet, A Emirian, M Groh, B Nebbadlechani, E Weiss, E BilleAbstract:Cefoxitin could be an alternative to carbapenems in extended-spectrum-beta-lactamase-producing Escherichia coli (ESBL-EC) infections. However, pharmacological and clinical data regarding Cefoxitin are limited. Using a recent pharmacological model and the MICs of ESBL-EC collected from pyelonephritis, we determined the probabilities to reach four pharmacological targets: free Cefoxitin concentrations above the MIC during 50% and 100% of the administration interval (T>MIC = 50% and T>MIC = 100%, respectively) and free Cefoxitin concentrations above 4× MIC during 50% and 100% of the administration interval (T>4MIC = 50% and T>4MIC = 100%, respectively). Cefoxitin could be used to treat ESBL-EC pyelonephritis, but administration modalities should be optimized according to MICs in order to reach pharmacological targets.
Michel Arthur - One of the best experts on this subject based on the ideXlab platform.
-
in vitro activity of Cefoxitin and imipenem against mycobacterium abscessus complex
Clinical Microbiology and Infection, 2014Co-Authors: Marie Lavollay, Vincent Dubee, Beate Heym, Jeanlouis Herrmann, J L Gaillard, L Gutmann, Michel ArthurAbstract:The in vitro activity of Cefoxitin and imipenem was compared for 43 strains of the Mycobacterium abscessus complex, mostly isolated from cystic fibrosis patients. The MICs of imipenem were lower than those of Cefoxitin, although the number of imipenem-resistant strains was higher according to the CLSI breakpoints. Strain comparisons indicated that the MICs of Cefoxitin were significantly higher for Mycobacterium bolletii than for M. abscessus. The MICs of both β-lactams were higher for the rough morphotype than for the smooth morphotype. The clinical impact of the in vitro difference between the activity of imipenem and that of Cefoxitin remains to be determined.
Sheelagh Frame - One of the best experts on this subject based on the ideXlab platform.
-
single dose cefotetan or Cefoxitin versus multiple dose Cefoxitin as prophylaxis in patients undergoing appendectomy for acute nonperforated appendicitis
Journal of The American College of Surgeons, 1995Co-Authors: Michael A. Liberman, Sheelagh Frame, Kevin L Greason, J J RaglandAbstract:OBJECTIVE: A prospective, double-blind study was performed to examine the effects of prophylactic cefotetan and Cefoxitin in postoperative wound infection for patients with nonperforated acute appendicitis. METHODS: One hundred thirty-six of 179 patients with a clinical diagnosis of appendicitis were evaluated and divided into three groups: group 1 received 2 g cefotetan preoperatively, group 2 received 2 g Cefoxitin preoperatively, and group 3 received 2 g Cefoxitin preoperatively followed by three postoperative doses. RESULTS: The overall wound infection rate was 4.6 percent. Group 2 (single-dose Cefoxitin) had a significantly higher wound infection rate (11.1 percent) than group 1 (single-dose cefotetan) (zero percent) or group 3 (multiple-dose Cefoxitin) (1.9 percent). CONCLUSIONS: Single-dose cefotetan and multiple-dose Cefoxitin are equally effective. However, because of the greater convenience and markedly decreased cost, single-dose cefotetan is the prophylaxis of choice in appendectomy for nonperforated appendicitis.